07.01.2015 • News

J&J Buys License Option for Isis Pharma Bowel Drug

US over-the-counter drugmaker Johnson & Johnson will pay Isis Pharmaceuticals up to $835 million for the option to license three drugs targeting autoimmune diseases in the bowel.

Isis Pharmaceuticals said it will receive $35 million in an upfront payment and will be eligible to receive royalties on sales of the drugs.

Janssen Biotech, a unit of Johnson & Johnson, will have the right to license a drug from each of the programs once a candidate is identified, the Carlsbad, California-based developer said.

Article

The State of the US Specialty Chemicals Industry
Reshaping Specialty Chemicals Manufacturing

The State of the US Specialty Chemicals Industry

SOCMA's Jenn Klein examines how specialty chemical manufacturers — the invisible backbone behind pharmaceuticals, electronics, agriculture, and energy — are navigating supply chain shifts, policy uncertainty, and constant change while remaining resilient, disciplined, and focused on execution.

Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

Top-Feature

most read